Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time

ConditionHealthy Aging
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-85
SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

Time processing, the ability to process and encode temporal information, is essential for cognitive functioning and for a large number of daily life activities. In particular, the processing of durations of several seconds is central to cognition, impaired in several pathologies, and has been associated with cognitive changes with advancing age. While behavioral studies have been conducted to specify the neural bases of temporal cognition and their association with other cognitive functions, the mechanisms underlying age-related changes, and individual differences, remain unknown. The project will characterize ageing effects on timing mechanisms and their neural underpinnings. Building on recent advances from neuroscience and age-related cognitive changes, the project focuses on the precision of duration processing, that declines with age, and the associated neural bases. Participants will perform a duration judgement task while (a) electroencephalography, and (b) functional magnetic resonance imaging activity are simultaneously recorded to investigate age effects on structural and functional network connectivity. In addition, striatal dopamine will be measured using a FDOPA PETscan. Evaluation of other temporal cognition processes and general cognition will also be performed. This combination offers a unique opportunity to accurately specifying the neurophysiological underpinning of aging effects on time processing changes. This project will further our understanding of the variability of cognitive performance with advancing age, and contribute to identifying new measures of temporal impairments.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Membership of a social security scheme or beneficiary of such a scheme.

At least 7 years' schooling.

Acceptance and signature of the informed consent form

Fluency in French (as assessed by the project leader)

Disqualifiers

Persons under guardianship, curators or safeguard of justice.

Pregnant women, women in labor and nursing mothers

Chronic neurological conditions

Uncorrected visual difficulties

Trial population

Healthy participant with no diagnosed condition

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • FDOPA injection before PET imaging

    Radiation

    Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.

  • Time perception tasks

    Behavioral

    The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations

  • fMRI imaging

    Device

    Imaging of brain structure during the completion of the time perception task

  • EEG imaging

    Device

    Recording of neural dynamics during the completion of the time perception task

  • 3 year follow-up

    Behavioral

    Behavioral and EEG follow-up (for older adults only)

Treatment groups

130 Participants
are divided into 2 treatment groups
Group A: Young healthy volunteers4 interventions
Group B: Older healthy volunteers5 interventions

Trial outcomes

Primary outcomes

1

EEG phase lag index differences between group

Functional connectivity (EEG phase lag index (PLI) in each frequency band) differences between young and older adults during completion of the duration comparison task

Time frame
Through study completion, an average of 3 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.